CA2437899A1 - Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea - Google Patents
Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea Download PDFInfo
- Publication number
- CA2437899A1 CA2437899A1 CA002437899A CA2437899A CA2437899A1 CA 2437899 A1 CA2437899 A1 CA 2437899A1 CA 002437899 A CA002437899 A CA 002437899A CA 2437899 A CA2437899 A CA 2437899A CA 2437899 A1 CA2437899 A1 CA 2437899A1
- Authority
- CA
- Canada
- Prior art keywords
- immunogen
- vaccine
- cfa
- immune response
- sta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A vaccine delivered by transcutaneous immunization provides an effective treatment against infections by pathogens such as, for example, enterotoxigenic Escherichia coli (ETEC) and/or for symptoms of diarrheal disease caused thereby. For example, one, two, three, four, five or more antigens derived from ETEC and capable of inducing an antigen-specific immune response (e.g., toxins, colonization or virulence factors) and one or more optional adjuvant (e.g., whole bacterial ADP-ribosylating exotoxins, B
subunits or toxoids thereof, detoxified mutants and derivatives thereof) are used to manufacture vaccines or to induce systemic and/or mucosal immunity.
subunits or toxoids thereof, detoxified mutants and derivatives thereof) are used to manufacture vaccines or to induce systemic and/or mucosal immunity.
Claims
We Claim:
1. An immunogen for transcutaneous immunization, wherein said immunogen is comprised of one or more antigens in effective amounts to induce an immune response against one or more strains of enterotoxigenic Escherichia coli (ETEC).
2. An immunogen according to Claim 1 further comprising at least one adjuvant.
3. An immunogen according to Claim 2, wherein the adjuvant is an ADP-ribosylating exotoxin or a derivative thereof having adjuvant activity.
4. An immunogen according to Claim 1, wherein the adjuvant is selected from the group consisting of cholera toxin (CT), Escherichia coli heat-labile enterotoxin (LT), and mutants thereof having adjuvant activity.
5. An immunogen according to any one of Claims 1-4, wherein at least one of said antigens induces an immune response against an E. coli colonization factor antigen (CFA).
6. An immunogen according to Claim 5, wherein the E. coli colonization factor antigen is selected from the group consisting of CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS17, and PCF 0166.
7. An immunogen according to any one of Claims 1-4, wherein at least one of said antigens induces an immune response against E. coli enterotoxin STa.
8. An immunogen according to any one of Claims 1-4, wherein the one or more antigens induce an immune response against at least CS3 and CS6; CS3 and CFA/I;
CS6 and CFA/I; CS3 and STa; CS6 and STa; or CFA/I and STa.
9. An immunogen according to any one of Claims 1-4, wherein the one or more antigens induce an immune response against at least CFA/I, CS3 and CS6; CF3, and STa; CFA/I, CS3 and STa; CFA/I, CS6 and STa; or CFA/I, CS3, CS6 and STa.
10. A vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of a patch and an immunogen according to any one of Claims 1-9.
11. A subunit vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of an immunogen according to any one of Claims 1-9 which is chemically synthesized, recombinantly produced, at least partially purified, or combinations thereof in cell-free form.
12. A whole-cell vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of an immunogen according to any one of Claims 1-9 in whole-cell form.
13. Use of immunogen or vaccine according to any one of Claims 1-12 to induce an immune response against one or more strains of ETEC.
14. Use of immunogen or vaccine according to any one of Claims 1-12 to treat and/or prevent one or more disease symptoms associated with traveler's diarrhea.
15. The use according to Claim 13 or 14 further comprising chemical and/or physical penetration enhancement.
16. Use of effective amounts of one or more antigens for manufacture of an immunogen or vaccine which induces an immune response against one or more strains of ETEC by transcutaneous immunization.
17. Use of effective amounts of at least one adjuvant and one or more antigens for manufacture of an immunogen or vaccine which induces an immune response against one or more strains of ETEC by transcutaneous immunization.
1. An immunogen for transcutaneous immunization, wherein said immunogen is comprised of one or more antigens in effective amounts to induce an immune response against one or more strains of enterotoxigenic Escherichia coli (ETEC).
2. An immunogen according to Claim 1 further comprising at least one adjuvant.
3. An immunogen according to Claim 2, wherein the adjuvant is an ADP-ribosylating exotoxin or a derivative thereof having adjuvant activity.
4. An immunogen according to Claim 1, wherein the adjuvant is selected from the group consisting of cholera toxin (CT), Escherichia coli heat-labile enterotoxin (LT), and mutants thereof having adjuvant activity.
5. An immunogen according to any one of Claims 1-4, wherein at least one of said antigens induces an immune response against an E. coli colonization factor antigen (CFA).
6. An immunogen according to Claim 5, wherein the E. coli colonization factor antigen is selected from the group consisting of CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS17, and PCF 0166.
7. An immunogen according to any one of Claims 1-4, wherein at least one of said antigens induces an immune response against E. coli enterotoxin STa.
8. An immunogen according to any one of Claims 1-4, wherein the one or more antigens induce an immune response against at least CS3 and CS6; CS3 and CFA/I;
CS6 and CFA/I; CS3 and STa; CS6 and STa; or CFA/I and STa.
9. An immunogen according to any one of Claims 1-4, wherein the one or more antigens induce an immune response against at least CFA/I, CS3 and CS6; CF3, and STa; CFA/I, CS3 and STa; CFA/I, CS6 and STa; or CFA/I, CS3, CS6 and STa.
10. A vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of a patch and an immunogen according to any one of Claims 1-9.
11. A subunit vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of an immunogen according to any one of Claims 1-9 which is chemically synthesized, recombinantly produced, at least partially purified, or combinations thereof in cell-free form.
12. A whole-cell vaccine suitable for transcutaneous immunization, wherein said vaccine is comprised of an immunogen according to any one of Claims 1-9 in whole-cell form.
13. Use of immunogen or vaccine according to any one of Claims 1-12 to induce an immune response against one or more strains of ETEC.
14. Use of immunogen or vaccine according to any one of Claims 1-12 to treat and/or prevent one or more disease symptoms associated with traveler's diarrhea.
15. The use according to Claim 13 or 14 further comprising chemical and/or physical penetration enhancement.
16. Use of effective amounts of one or more antigens for manufacture of an immunogen or vaccine which induces an immune response against one or more strains of ETEC by transcutaneous immunization.
17. Use of effective amounts of at least one adjuvant and one or more antigens for manufacture of an immunogen or vaccine which induces an immune response against one or more strains of ETEC by transcutaneous immunization.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26801601P | 2001-02-13 | 2001-02-13 | |
US60/268,016 | 2001-02-13 | ||
US30411001P | 2001-07-11 | 2001-07-11 | |
US60/304,110 | 2001-07-11 | ||
US31048301P | 2001-08-08 | 2001-08-08 | |
US31044701P | 2001-08-08 | 2001-08-08 | |
US60/310,483 | 2001-08-08 | ||
US60/310,447 | 2001-08-08 | ||
PCT/US2002/004254 WO2002064162A2 (en) | 2001-02-13 | 2002-02-13 | Vaccine for transcutaneous immunization |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2437899A1 true CA2437899A1 (en) | 2002-08-22 |
CA2437899C CA2437899C (en) | 2012-05-15 |
Family
ID=27500924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2437899A Expired - Fee Related CA2437899C (en) | 2001-02-13 | 2002-02-13 | Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea |
Country Status (12)
Country | Link |
---|---|
US (1) | US7527802B2 (en) |
EP (1) | EP1372708B1 (en) |
JP (2) | JP2005504002A (en) |
AT (1) | ATE398461T1 (en) |
AU (1) | AU2002250071B2 (en) |
CA (1) | CA2437899C (en) |
CY (1) | CY1111030T1 (en) |
DE (1) | DE60227157D1 (en) |
DK (1) | DK1372708T3 (en) |
ES (1) | ES2310201T3 (en) |
PT (1) | PT1372708E (en) |
WO (1) | WO2002064162A2 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
DE60227157D1 (en) * | 2001-02-13 | 2008-07-31 | Us Gov Sec Army | IMPREGENTS FOR TRANSCUTANEOUS IMMUNIZATION AGAINST TRAVEL DIARRHOUS |
US20040109869A1 (en) * | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
CA2477273A1 (en) | 2002-02-25 | 2003-09-18 | U.S. Army Medical Research And Materiel Command | Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
TWI350174B (en) * | 2003-03-12 | 2011-10-11 | Wyeth Corp | Adjuvanted bovine vaccines |
EP1543836A1 (en) * | 2003-12-17 | 2005-06-22 | Berna Biotech AG | Recombinant Vibrio cholerae strain and vaccine comprising said strain |
US20050281789A1 (en) * | 2004-05-20 | 2005-12-22 | Mangala Rao | Transcutaneous and/or transdermal transport of materials |
WO2006007366A2 (en) * | 2004-06-15 | 2006-01-19 | Iomai Corporation | SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS |
US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
WO2006039659A1 (en) * | 2004-10-02 | 2006-04-13 | Sri International | Bioadhesive delivery system for transmucosal delivery of beneficial agents |
AU2006205128B2 (en) | 2005-01-11 | 2013-03-28 | The United States Of America As Represented By The Secretary Of The Navy | Adhesin as immunogen against Escherichia coli |
FR2887457B1 (en) * | 2005-06-23 | 2007-10-05 | Fond Bettencourt Schueller | TRANSCUTANE TARGETING VACCINATION |
ES2514316T3 (en) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
WO2007117339A2 (en) | 2006-01-11 | 2007-10-18 | The United States Of America As Respresented By The Secretary Of The Navy | Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli |
EP1981536A4 (en) * | 2006-02-01 | 2012-03-14 | Gotovax Ab | Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria |
US8287885B2 (en) | 2007-09-12 | 2012-10-16 | Novartis Ag | GAS57 mutant antigens and GAS57 antibodies |
FR2924349B1 (en) | 2007-12-03 | 2010-01-01 | Dbv Tech | ALLERGEN DISENSIBILITY METHOD |
FR2924350B1 (en) * | 2007-12-03 | 2010-08-13 | Dbv Tech | METHOD AND COMPOSITIONS FOR SKIN VACCINATION |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
NZ586430A (en) | 2007-12-21 | 2012-09-28 | Novartis Ag | Mutant forms of streptolysin o (slo) |
US9169327B2 (en) * | 2008-03-12 | 2015-10-27 | Rowan University | Targeting of podoplanin with lectin for use in the prevention and treatment of cancer |
US7927586B2 (en) * | 2008-07-08 | 2011-04-19 | South Dakota State University | Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli |
WO2010013350A1 (en) | 2008-08-01 | 2010-02-04 | Aspion株式会社 | S/o type transdermal immunizing agent |
WO2010027473A2 (en) | 2008-09-03 | 2010-03-11 | Board Of Trustees Of Michigan State University | Immunogenic escherichia coli heat stable enterotoxin |
MX2011007456A (en) | 2009-01-12 | 2011-08-03 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria. |
AU2010220103A1 (en) | 2009-03-06 | 2011-09-22 | Novartis Ag | Chlamydia antigens |
US20100286600A1 (en) * | 2009-05-08 | 2010-11-11 | Bommannan D Bommi | Transdermal patch device |
SI2432455T1 (en) | 2009-05-18 | 2015-04-30 | Sigmoid Pharma Limited | Composition comprising oil drops |
JP5615814B2 (en) * | 2009-06-10 | 2014-10-29 | 久光製薬株式会社 | Microneedle device |
EP2442826B1 (en) | 2009-06-15 | 2015-07-08 | National University of Singapore | Influenza vaccine, composition, and methods of use |
EP2464341B1 (en) | 2009-08-12 | 2022-07-06 | Sublimity Therapeutics Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
EP2485752A4 (en) * | 2009-10-09 | 2013-07-31 | Univ South Dakota | Enterotoxigenic e. coli fusion protein vaccines |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
US20130189303A1 (en) | 2011-08-02 | 2013-07-25 | Yan Zhou | Recombinant swine influenza virus and uses thereof |
AU2012307540B2 (en) | 2011-09-12 | 2016-09-22 | Scandinavian Biopharma Holding Ab | Method for increasing ETEC CS6 antigen presentation on cell surface and products obtainable thereof |
US9511130B2 (en) | 2011-09-14 | 2016-12-06 | Glaxosmithkline Biologicals Sa | Escherichia coli vaccine combination |
RS56709B1 (en) | 2011-12-06 | 2018-03-30 | Valneva Austria Gmbh | Aluminium compounds for use in therapeutics and vaccines |
WO2014008475A2 (en) | 2012-07-05 | 2014-01-09 | The Ohio State University | Compositions and methods related to viral vaccines |
GB201212010D0 (en) * | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
WO2014044690A1 (en) | 2012-09-18 | 2014-03-27 | Valneva Austria Gmbh | Improved vaccines |
WO2014047625A1 (en) | 2012-09-24 | 2014-03-27 | Montana State University | Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use |
JP6403680B2 (en) * | 2012-11-19 | 2018-10-10 | ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy | Recombinant polypeptide constructs containing multiple toxigenic E. coli pilus subunits |
CN105051537B (en) * | 2012-12-28 | 2019-04-12 | 塞尔雷斯蒂斯有限公司 | Cell-mediated immune response test |
WO2014138748A1 (en) * | 2013-03-08 | 2014-09-12 | Research Institute At Nationwide Children's Hospital | Transcutaneous dosage formulation |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
US10300136B2 (en) | 2013-12-16 | 2019-05-28 | Massachusetts Institute Of Technology | Micromolded or 3-D printed pulsatile release vaccine formulations |
US9649279B2 (en) | 2013-12-16 | 2017-05-16 | Massachusetts Institute Of Technology | Fortified micronutrient salt formulations |
CA2966801A1 (en) | 2014-11-07 | 2016-05-12 | Sigmoid Pharma Limited | Compositions comprising cyclosporin |
WO2016149482A2 (en) * | 2015-03-17 | 2016-09-22 | Vanderbilt University | Cs21 and lnga protein vaccines |
EP3328424A1 (en) * | 2015-07-31 | 2018-06-06 | Bayer Animal Health GmbH | Enhanced immune response in porcine species |
US11324816B2 (en) | 2015-08-31 | 2022-05-10 | Technovax, Inc. | Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine |
US10494406B2 (en) | 2015-11-30 | 2019-12-03 | Idemitsu Kosan Co., Ltd. | Vaccine antigen with increased immunogenicity |
CN106267191A (en) * | 2016-09-03 | 2017-01-04 | 山西纳安生物科技有限公司 | Nano antibody biological medicament Percutaneously administrable preparation system and preparation method and application |
WO2019021954A1 (en) * | 2017-07-24 | 2019-01-31 | 株式会社バイオセレンタック | Vaccine adjuvant and microneedle preparation |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US3837340A (en) | 1971-10-20 | 1974-09-24 | Lilly Co Eli | Device for administering immunication against virus |
US3948263A (en) * | 1974-08-14 | 1976-04-06 | Minnesota Mining And Manufacturing Company | Ballistic animal implant |
US3982536A (en) | 1974-11-15 | 1976-09-28 | Minnesota Mining And Manufacturing Company | Ballistic inoculation of animals and projectile therefor |
US4196191A (en) * | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
US4285931A (en) * | 1978-01-30 | 1981-08-25 | Merck & Co., Inc. | E. coli enterotoxin vaccine for veterinary and human use |
US4220584A (en) | 1978-01-30 | 1980-09-02 | Merck & Co., Inc. | E. coli enterotoxin vaccine for veterinary and human use |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
US4455142A (en) * | 1980-07-07 | 1984-06-19 | Alza Corporation | Method of coadministering an antigen and an immunopotentiator |
US4761372A (en) | 1981-01-12 | 1988-08-02 | New York University | Mutant enterotoxin of E. coli |
US4411888A (en) | 1981-06-22 | 1983-10-25 | The University Of Rochester | Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli |
US4484923A (en) | 1982-03-25 | 1984-11-27 | Alza Corporation | Method for administering immunopotentiator |
US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4587044A (en) * | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US4725271A (en) * | 1983-10-17 | 1988-02-16 | Enquay Pharmaceutical Associates | Synthetic resin matrix drug storage and topical drug delivery dressing for veterinary usage |
US4743588A (en) * | 1984-06-13 | 1988-05-10 | Allergan Pharmaceuticals, Inc. | Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents |
US5008050A (en) * | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US5308835A (en) * | 1984-07-09 | 1994-05-03 | Praxis Biologics, Inc. | Production of the E. coli LT-B enterotoxin subunit |
US5008111A (en) * | 1984-10-11 | 1991-04-16 | Schering Corporation | Physiological means of enhancing transdermal delivery of drugs |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4692462A (en) | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
US4921757A (en) * | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US4732892A (en) * | 1985-07-12 | 1988-03-22 | American Home Products Corporation | L-α-amino acids as transdermal penetration enhancers |
DE3527893A1 (en) | 1985-08-03 | 1987-02-05 | Merck Patent Gmbh | EPICUTANE TEST PLASTER |
JPH0768124B2 (en) | 1985-08-27 | 1995-07-26 | グリ−ジンク フア−マシユ−テイカルズ リミテツド | Zinc glycerolate complex and additions for pharmaceutical applications |
US4970206A (en) | 1985-11-29 | 1990-11-13 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4764381A (en) | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
US5270346A (en) | 1986-01-31 | 1993-12-14 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US5204339A (en) * | 1986-01-31 | 1993-04-20 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US5142044A (en) | 1986-04-23 | 1992-08-25 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US5041439A (en) | 1986-06-13 | 1991-08-20 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
US5326790A (en) | 1986-11-19 | 1994-07-05 | Dermatologic Research Corporation | Administration of skin medications by use of dicarboxylic acids and derivatives |
US4876249A (en) | 1987-01-12 | 1989-10-24 | Rajadhyaksha Vithal J | Compositions and method comprising heterocyclic compounds containing two heteroatoms |
US4917688A (en) * | 1987-01-14 | 1990-04-17 | Nelson Research & Development Co. | Bandage for transdermal delivery of systemically-active drug |
US5049387A (en) | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
US5045317A (en) | 1987-07-16 | 1991-09-03 | The Regents Of The University Of California | Enhancing the cutaneous penetration of pharmacologically active agents |
JP2594441B2 (en) * | 1987-07-16 | 1997-03-26 | 日本鋳造株式会社 | Method for producing free-cutting high-temperature low-thermal-expansion cast alloy |
JP2520262B2 (en) | 1987-08-21 | 1996-07-31 | 春幸 川原 | Patch test material |
US5059189A (en) | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
AU614092B2 (en) * | 1987-09-11 | 1991-08-22 | Paul Max Grinwald | Improved method and apparatus for enhanced drug permeation of skin |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
US4917895A (en) * | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
US5234959A (en) | 1988-04-08 | 1993-08-10 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US5472946A (en) | 1988-04-08 | 1995-12-05 | Peck; James V. | Transdermal penetration enhancers |
JP2849632B2 (en) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | Vaccine preparation |
US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
US5164406A (en) | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
US4960771A (en) | 1988-07-12 | 1990-10-02 | Rajadhyaksha Vithal J | Oxazolidinone penetration enhancing compounds |
US4892737A (en) * | 1988-09-22 | 1990-01-09 | University Of Florida | Composition and method for enhancing permeability of topical drugs |
US5032402A (en) | 1988-10-27 | 1991-07-16 | The University Of Kentucky Research Foundation | 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
IE62662B1 (en) | 1989-01-06 | 1995-02-22 | Elan Corp Plc | Use of nicotine in the treatment of conditions susceptible to said treatment |
CA2045469A1 (en) * | 1989-02-17 | 1990-08-18 | Alan L. Weiner | Lipid excipient for nasal delivery and topical application |
US5534260A (en) | 1989-02-23 | 1996-07-09 | University Of Utah | Percutaneous drug delivery system |
US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
US5411738A (en) * | 1989-03-17 | 1995-05-02 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5162315A (en) | 1989-05-08 | 1992-11-10 | Rajadhyaksha Vithal J | Penetration enhancers |
US5028435A (en) | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US4956171A (en) | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
DE3924393A1 (en) | 1989-07-24 | 1991-01-31 | Roehm Gmbh | WATER-SOLUBLE PRESSURE-SENSITIVE SKIN ADHESIVE, THE USE THEREOF AND MEANS THEREFORE |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
US5518725A (en) * | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
EP0429842B1 (en) | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5279544A (en) * | 1990-12-13 | 1994-01-18 | Sil Medics Ltd. | Transdermal or interdermal drug delivery devices |
US5332576A (en) | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
EP0576605A4 (en) * | 1991-03-19 | 1994-06-08 | Vithal J Rajadhyaksha | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
US5256422A (en) | 1991-03-28 | 1993-10-26 | Micro Vesicular Systems, Inc. | Lipid vesicle containing water-in-oil emulsions |
DE4115849A1 (en) * | 1991-05-15 | 1992-11-19 | Lohmann Therapie Syst Lts | PENETRATION PROMOTING SUBSTANCE |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
GB9114346D0 (en) | 1991-07-03 | 1991-08-21 | Dow Corning Sa | A method of accelerating drug permeation |
US5215520A (en) * | 1991-09-17 | 1993-06-01 | Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for delivering an active substance topically or percutaneously |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
WO1993009842A1 (en) | 1991-11-13 | 1993-05-27 | Elan Corporation, Plc | Drug delivery device |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5260066A (en) | 1992-01-16 | 1993-11-09 | Srchem Incorporated | Cryogel bandage containing therapeutic agent |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5614212A (en) * | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US5756117A (en) * | 1992-04-08 | 1998-05-26 | International Medical Asscociates, Inc. | Multidose transdermal drug delivery system |
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
CA2097163C (en) * | 1992-06-01 | 2002-07-30 | Marianna Foldvari | Topical patch for liposomal drug delivery system |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
PT652758E (en) * | 1992-06-18 | 2000-04-28 | Harvard College | DIFTERIA TOXIN VACCINES |
US5464386A (en) | 1992-08-17 | 1995-11-07 | Genetronics, Inc. | Transdermal drug delivery by electroincorporation of vesicles |
US5462743A (en) | 1992-10-30 | 1995-10-31 | Medipro Sciences Limited | Substance transfer system for topical application |
GB2273044B (en) * | 1992-12-02 | 1997-04-09 | Pacific Chem Co Ltd | Medicinal patches for percutaneous administration |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
ATE386800T1 (en) * | 1993-03-17 | 2008-03-15 | Us Gov Health & Human Serv | IMMUNOGENIC CHIMERAS COMPRISING NUCLEIC ACID SEQUENCES ENCODING ENDOPLASMATIC RETICULUM SIGNAL SEQUENCE PEPTIDES AND AT LEAST ONE OTHER PEPTIDE, THEIR USE IN VACCINES AND FOR THE TREATMENT OF DISEASES |
US5723114A (en) * | 1993-03-19 | 1998-03-03 | Cellegy Pharmaceuticals Inc. | Penetration enhancing compositions and methods of their use |
US5614503A (en) * | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
US5458140A (en) * | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5445611A (en) | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
US6022315A (en) * | 1993-12-29 | 2000-02-08 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system including network access |
JP3021661B2 (en) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | Transdermal release devices for drug-containing adhesive composites |
ES2316148T3 (en) * | 1994-03-23 | 2009-04-01 | Ohio University | COMPACTED NUCLEIC ACIDS AND ITS SUPPLY TO CELLS. |
US5536263A (en) | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
IL113034A (en) * | 1994-04-05 | 2000-02-17 | Astra Ab | Topical dressing |
US5733762A (en) * | 1994-04-28 | 1998-03-31 | I.D.M. Immuno-Designed Molecules | Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells |
DE4416927C1 (en) * | 1994-05-13 | 1995-08-31 | Lohmann Therapie Syst Lts | Device for release of active agents from melt-type adhesive |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide vaccne for papillomavirus |
US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
AU5740496A (en) * | 1995-05-22 | 1996-12-11 | General Hospital Corporation, The | Micromechanical device and method for enhancing delivery of compounds through the skin |
US5914114A (en) * | 1995-06-02 | 1999-06-22 | The United States Of America As Represented By The Secretary Of The Army | Method of raising antibodies against E. coli of the family CS4-CFA/I |
US5637576A (en) * | 1995-06-05 | 1997-06-10 | Synsorb Biotech, Inc. | Treatment of traveller's diarrhea |
US5627163A (en) * | 1995-06-05 | 1997-05-06 | Synsorb Biotech, Inc. | Treatment of traveller's diarrhea |
WO1996040961A1 (en) * | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US5720948A (en) * | 1995-11-07 | 1998-02-24 | Helene Curtis Inc. | Non-ionic surfactant emulsion vehicles and their use for deposition of drug into and across skin |
US5736154A (en) * | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
US6033684A (en) * | 1996-08-28 | 2000-03-07 | Jonor, Inc. | Compositions and methods for wound management |
US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
US5738647A (en) * | 1996-09-27 | 1998-04-14 | Becton Dickinson And Company | User activated iontophoretic device and method for activating same |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
CA2268957C (en) * | 1996-10-25 | 2008-04-29 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
US5910306A (en) * | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
DE19653605C2 (en) * | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Adhesives and binders for dermal or transdermal therapy systems and their use for producing a transdermal therapy system |
US6348450B1 (en) * | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US20040258703A1 (en) * | 1997-11-14 | 2004-12-23 | The Government Of The Us, As Represented By The Secretary Of The Army | Skin-active adjuvants for transcutaneous immunization |
WO2000035357A1 (en) * | 1998-12-18 | 2000-06-22 | Sontra Medical, Inc. | Methods and apparatus for enhancement of transdermal transport |
EP1356821B1 (en) * | 1998-02-25 | 2007-06-20 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response |
ES2289200T3 (en) * | 1998-02-25 | 2008-02-01 | The Government Of The United States, As Represented By The Secretary Of The Army | USE OF IMPROVERS FOR SKIN PENETRATION AND BARRIER ALTERATION AGENTS TO IMPROVE THE TRANSCUTANEOUS IMMUNE RESPONSE. |
US6173202B1 (en) * | 1998-03-06 | 2001-01-09 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
US6033673A (en) * | 1998-03-18 | 2000-03-07 | The Administrators Of Tulane Educational Fund | Double mutant enterotoxin for use as an adjuvant |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
JP4275768B2 (en) * | 1998-06-18 | 2009-06-10 | 久光製薬株式会社 | Aqueous adhesive paste |
US6210672B1 (en) * | 1998-10-20 | 2001-04-03 | Torrey Pines Institute For Molecular Studies | Topical immunostimulation to induce Langerhans cell migration |
US6180136B1 (en) * | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
SE515285C2 (en) * | 1998-12-18 | 2001-07-09 | Sbl Vaccin Ab | Oral vaccine for diarrhea |
JP4932086B2 (en) * | 1999-04-08 | 2012-05-16 | インターセル ユーエスエイ、インコーポレイテッド | Dry formulation for transcutaneous immunization |
US6348212B2 (en) * | 1999-05-18 | 2002-02-19 | Lectec Corporation | Treating traumatic burns or blisters of the skin |
US6379324B1 (en) * | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
US6190367B1 (en) * | 1999-09-22 | 2001-02-20 | Becton, Dickinson And Company | Medical site prep device |
ATE349531T1 (en) * | 2000-04-20 | 2007-01-15 | Univ Maryland | ISOLATION AND CHARACTERIZATION OF THE CSA OPERON (ETEC-CS4 PILI) AND METHOD OF ITS APPLICATION |
DE60227157D1 (en) * | 2001-02-13 | 2008-07-31 | Us Gov Sec Army | IMPREGENTS FOR TRANSCUTANEOUS IMMUNIZATION AGAINST TRAVEL DIARRHOUS |
US20040109869A1 (en) * | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
EP1450855B1 (en) * | 2001-05-23 | 2009-08-26 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
US20030157159A1 (en) * | 2002-01-15 | 2003-08-21 | Franklin Lanny Udell | Prevention and treatment of digestive tract infections |
US6869602B2 (en) * | 2002-02-20 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Army | Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells |
CA2477273A1 (en) * | 2002-02-25 | 2003-09-18 | U.S. Army Medical Research And Materiel Command | Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections |
US20040137004A1 (en) * | 2002-03-19 | 2004-07-15 | Glenn Gregory M | Patch for transcutaneous immunization |
EP1708744A4 (en) * | 2003-12-09 | 2009-07-15 | Intercell Usa Inc | Gm1 binding deficient exotoxins for use as immunoadjuvants |
EP1928537B1 (en) * | 2005-09-02 | 2015-01-21 | Intercell USA, Inc. | Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs |
-
2002
- 2002-02-13 DE DE60227157T patent/DE60227157D1/en not_active Expired - Lifetime
- 2002-02-13 AT AT02718962T patent/ATE398461T1/en active
- 2002-02-13 WO PCT/US2002/004254 patent/WO2002064162A2/en active Application Filing
- 2002-02-13 JP JP2002563955A patent/JP2005504002A/en active Pending
- 2002-02-13 EP EP02718962A patent/EP1372708B1/en not_active Expired - Lifetime
- 2002-02-13 US US10/467,887 patent/US7527802B2/en not_active Expired - Lifetime
- 2002-02-13 DK DK02718962T patent/DK1372708T3/en active
- 2002-02-13 PT PT02718962T patent/PT1372708E/en unknown
- 2002-02-13 CA CA2437899A patent/CA2437899C/en not_active Expired - Fee Related
- 2002-02-13 ES ES02718962T patent/ES2310201T3/en not_active Expired - Lifetime
- 2002-02-13 AU AU2002250071A patent/AU2002250071B2/en not_active Ceased
-
2008
- 2008-09-17 CY CY20081101003T patent/CY1111030T1/en unknown
-
2010
- 2010-04-01 JP JP2010085208A patent/JP2010180228A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20040146534A1 (en) | 2004-07-29 |
DK1372708T3 (en) | 2008-10-20 |
JP2010180228A (en) | 2010-08-19 |
CY1111030T1 (en) | 2015-06-11 |
EP1372708A2 (en) | 2004-01-02 |
CA2437899C (en) | 2012-05-15 |
WO2002064162A3 (en) | 2003-10-30 |
AU2002250071B2 (en) | 2008-02-14 |
WO2002064162A2 (en) | 2002-08-22 |
DE60227157D1 (en) | 2008-07-31 |
EP1372708B1 (en) | 2008-06-18 |
JP2005504002A (en) | 2005-02-10 |
ATE398461T1 (en) | 2008-07-15 |
PT1372708E (en) | 2008-09-29 |
ES2310201T3 (en) | 2009-01-01 |
US7527802B2 (en) | 2009-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2437899A1 (en) | Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea | |
Turnbull | Anthrax vaccines: past, present and future | |
Roy et al. | Outer membrane vesicles induce immune responses to virulence proteins and protect against colonization by enterotoxigenic Escherichia coli | |
US7056492B2 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing Mycoplasma bovis pneumonia in cattle | |
ES546038A0 (en) | A METHOD FOR PREPARING AN IMMUNOGEN CONJUGATE | |
Marzouqi et al. | Development of improved vaccines against whooping cough: current status | |
Faezi et al. | Protective efficacy of Pseudomonas aeruginosa type‐A flagellin in the murine burn wound model of infection | |
PT914153E (en) | Multivalent dtp-polio vaccines | |
AU4267093A (en) | Vaccine compositions for mucosal delivery | |
OA12640A (en) | Mycoplasma bovis vaccine methods of reducing pneumonia in animals. | |
KR970703164A (en) | Treatment and Prevention of Helicobacter Infection (TREATMENT AND PREVENTION OF HELICOBACTER INFECTION) | |
KR101818901B1 (en) | Inactivated vaccine composition of Actinobacillus pleuroneumoniae inactivated bacterin and N or C fragments of Actinobacillus pleuroneumniae ApxIA, ApxIIA, ApxIIIA inactivated toxin | |
CA2022420A1 (en) | Escherichia coli vaccine | |
Duan et al. | Major virulence factors of enterotoxigenic Escherichia coli in pigs | |
Luo et al. | Immunogenicity and protective efficacy against enterotoxigenic Escherichia coli colonization following intradermal, sublingual, or oral vaccination with EtpA adhesin | |
WO2003000204A8 (en) | Multivalent mycoplasma bacterin | |
Isaka et al. | Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria–pertussis–tetanus (DPT) combination vaccine | |
AU663864B2 (en) | Preparation and use of formalin-killed colonization-factor-antigen (CFA)-expressing E. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic E. coli bacteria in humans | |
Holmgren et al. | Oral cholera vaccines | |
Finger et al. | Bordetella | |
Xing et al. | Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo | |
Yang et al. | Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT‑Hc in mice | |
Shaughnessy et al. | Production of Potent Inactivated Vaccines with Ultraviolet Irradiation: IV. Vaccination Against Bacillary Dysentery | |
Sansonetti | Vaccination against typhoid fever: A century of research. End of the beginning or beginning of the end? | |
Sabbaj et al. | Mucosal immunisation for enteric diseases: Current practice and future prospects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150213 |